12
Aug
2010
Posted in I - Series B, Q - 3Q10, R - NORTH EAST, X - Cardiology, X - G-Protein, X - Pain, XX - PA
Trevena (Berwyn, PA) a clinical-stage small molecule company focused on G-protein coupled receptor targeting for heart failure and pain, closed a $35M Series B funding from existing investors. Participants include Polaris Venture Partners, New Enterprise Associates, Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company.
12
Aug
2010
Posted in I - Series C, Q - 3Q10, R - WEST, X - Device (Aneurysm), XX - CA
TriVascular (Santa Rosa, CA) a commercial-stage medical device company focused on endovascular repair devices for the treatment of abdominal aortic aneurysms, closed a $60M Series C financing. Participants include Pinnacle Ventures, New Enterprise Associates, Delphi Ventures, MPM Capital and Kearny Venture Partners.
13
Jul
2010
Posted in I - Series C, Q - 2Q10, R - SOUTH EAST, X - Device (Delivery), X - Vaccines, XX - NC
Liquidia Technologies (Research Triangle Park, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $5M Series C financing, bringing the total round to $25M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside, Firelake Capital and PPD
18
Jun
2010
07
Jun
2010
Posted in I - Series E, Q - 2Q10, R - MID WEST, X - Device (Spine), XX - MN
Anulex Technologies (Minnetonka, MN) a commercial-stage medical device company focused on herniated discectomy procedures, closed a $18.3M Series E financing. Participants include Hatteras Late Stage VC Fund, Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners.
28
May
2010
12
Apr
2010
Posted in I - Series C, Q - 1Q10, R - SOUTH EAST, X - Device (Delivery), X - Vaccines, XX - NC
Liquidia (Morrisville, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $13M Series C financing, bringing the total round to $20M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside and Firelake Capital.
30
Mar
2010
29
Mar
2010
22
Feb
2010
Posted in I - Series B, Q - 1Q10, R - SOUTH EAST, X - Biologics Mfg., XX - NC
PhaseBio Pharmaceuticals (Research Triangle Park, NC) a development-stage biopharma company focused on elastin-like fusion proteins for improved expression and purification of biological, closed a $25M Series B financing. Participants include New Enterprise Associates, Hatteras Venture Partners, Johnson & Johnson Development Corp. and Fletcher Spaght Ventures.